Skip to content
Study details
Enrolling now

Clozapine Trial to Prevent Violence in Schizophrenia

New York State Psychiatric Institute
NCT IDNCT05208190ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

280

Study length

about 5 years

Ages

18–65

Locations

7 sites in CA, GA, MD +2

About this study

Researchers are testing whether clozapine, a medication, can help prevent violence in people with schizophrenia who have a history of violent acts. Participants will be randomly assigned to receive either clozapine or their usual treatment (TAU). The trial will last for 1809 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Clozapine
  • 2.Take treatment as usual
PhasePhase 4
DrugClozapine
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

clozapine (Atypical antipsychotic; blocks dopamine and serotonin (higher efficacy for refractory schizophrenia))

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Positive symptoms and substance use

Body systems

Psychiatry / Mental Health